R & D

Print

NovelIC team has in-depth experience in various national and international R&D pre-competitive projects.

NovelIC is actively supporting partnerships in the EU Research Programs as SME and continuously looking for H2020 interdisciplinary and focused partnership on:

  • Contactless sensors
  • Wireless and wired communication
  • Signal processing solutions and implementations on target platforms or ASICs
  • Embedded HW/SW platforms, system demonstrators and field trails

 

NovelIC is listed on the Cordis database. 

We have R&D activities on:

  • 60 GHz Radar Sensor IPs (mm-wave IC, antenna systems and signal processing)
  • Technologies for Gbit Wireless Data Transfers (Cryptography)
  • Wireless controlled mobile platforms with data exchange
  • Data acquisition and control systems
  • New genertaion of bio-sensors enabled systems for medical use 

 

NovelIC has following pending patent applications:

  • Visual impaired support systems
  • Driver fatigue sensor
  • Seat occupation sensor
  • Vital signs sensor
  • Perimeter control sensor
  • Emotion Sensor
  • Parking Sensor
  • Gesture Sensor

 

In the scope of the European Horizon 2020 Programme and being part of the GLAM Project Consortia, NovelIC is participating in multidisciplinary R&D activities, targeting new sensor system development for medical use.

The major task of NovelIC in the GLAM Project is to contribute to system design and design of integrated portable device, based on novel photonic sensors.

As an innovative SME, NovelIC is also taking the role of the Exploitation manager in the project, providing the first interface for GLAM Technology transfer in the future product. 

 

GLAM – novel photonic based point-of-care device for cancer diagnosis.

 

 

 

GLAM’s disruptive technology will help oncologist to take better treatment decisions, approaching personalized medicine, in a cost-effective and non-invasive manner.

 

Coordinated by Leitat Technological Center in Spain, the 4-years Project joins recognized organisations: IBEC (ES), University of Twente (NL), WizSoft LTD (IL), Université libre de Bruxelles (BE), ICFO (ES), Radboud University Medical Center (NL), NOVELIC DOO (SB), OPTOCAP LTD (UK) and OBELIS SA (BE).

 

Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient responses to existing treatments. However outcome of this diagnosis is today still poor. Moreover, current technology to measure biomarker levels is expensive and sophisticated. Most cancer biomarker analysis use blood or biological tissues as the main source of material. These biopsies must be analyzed in specialized laboratories incurring in some limitations: high cost; specialized personnel and equipment; large amounts of biological material; long outcome delivery time; time consuming processes.

 

Therefore it exist a real need and urgency to have new diagnostic devices that provide diagnosis, prognosis, and monitoring data faster and with exquisite ultra-sensitivity on time to take the appropriate decisions to improve personalized diagnosis and therapy. The aim of GLAM project is to provide an innovative device to fulfill these requirements using soluble biomarkers for personalized diagnosis and therapy monitoring.

 

Specifically, GLAM will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine.

 

GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine. Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with other biomarker driven.

 

The project will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost.

 

For more information on the field, please contact us.

 

   
Copyright © 2015, NovelIC | All Rights Reserved. ISO